The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
and in the case of these SDLT inhibitors you know they're the first drugs that have really shown a profound impact on cardiovascular outcomes this is secondary prevention for cardiovascular disease in people who have already had an event into who also have type 2 diabetes so epic of flows and it's an amazing drug
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.